We also briefly explored the outcomes of patients treated with a TROP2 inhibitor (sacituzumab govitecan) retrospectively and found no difference in OS of patients with UC or HR+HER2− BC during the period with the treatment. This evidence concerns the gene TACSTD2 and breast cancer.